Showing results (111-120 of 321) with videos related to

Sort By:
Pageof 33
RMD Open|January 21, 2020
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritisDafna Gladman, Peter Nash, Hitoshi Goto, et al.
Therapeutic Advances in Musculoskeletal Disease|August 30, 2023
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2Atul Deodhar, Dafna Gladman, Rebecca Bolce, et al.
Arthritis and Rheumatism|March 2, 2006
Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populationsWalter P Maksymowych, Proton Rahman, Jeff P Reeve, et al.
The Journal of Rheumatology|July 9, 2008
Genetics of psoriasis and psoriatic arthritis: update and future directionKristina Callis Duffin, Vinod Chandran, Dafna D Gladman, et al.
Clinical Rheumatology|December 18, 2008
Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritisAnthony Russell, Ariel Beresniak, Louis Bessette, et al.
The Journal of Rheumatology|December 2, 2008
Association of interleukin 23 receptor variants with psoriatic arthritisProton Rahman, Robert D Inman, Walter P Maksymowych, et al.
Scientific Reports|May 19, 2015
Integrated genomics identifies convergence of ankylosing spondylitis with global immune mediated disease pathwaysMohammed Uddin, Dianne Codner, S M Mahmud Hasan, et al.
Arthritis and Rheumatism|April 3, 2008
Association of interleukin-23 receptor variants with ankylosing spondylitisProton Rahman, Robert D Inman, Dafna D Gladman, et al.
Rheumatology (Oxford, England)|December 6, 2018
Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumabLaura C Coates, Proton Rahman, Eliofotisti Psaradellis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2014
Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritisPhilip Mease, Joachim Sieper, Filip Van den Bosch, et al.
Pageof 33